IL10 and B-cell chronic lymphocytic leukemia: Additionally, umbralisib preserves IL-10 synthesis while inhibiting Th1/Th2-mediated inflammatory cytokine cascades, lowering immune-mediated complication risks in preclinical CLL studies (22).